What is the most clinically effective and cost effective non-FDG tracer for use in PET-CT for staging and assessment of patients with suspected recurrent prostate cancer? : in response to an enquiry from the PET-CT Working Group.
Healthcare Improvement Scotland.
Includes bibliographical references (pages 14-16).
Description from online resource; title from PDF caption (Healthcare Improvement Scotland, viewed 5 August 2022)
Prostate